Insight Molecular Diagnostics Inc. · NASDAQ:IMDX
Insight Molecular Diagnostics — Investor Presentation (February 2026)
36 slides from Insight Molecular Diagnostics's investor presentation, Feb 11, 2026
Slide 1: Investor Presentation
Investor | Presentation ul NASDAQ:IMDX aT February 2026 iMDxinc.com ne
Slide 2: About this Presentation
About this Presentation The information contained in this presentation has been prepared by Insight Molecular Diagnostics Inc. (f/k/a Oncocyte C id its ively, the “Company,” “Insight,” “iMDx,” “we,” “our,” “us”) and contains information pertaining to the business and operations of the Company, The i
Slide 3: Mission
; M D ° Insight Molecular Diagnostics MISSION Decentralize access to novel molecular diagnostic testing to improve patient outcomes
Slide 4: Experienced Leadership
™ Dx Insight Molecular Diagnostics Experienced Leadership Pioneering Molecular Diagnostics & Disruptive Growth Josh Riggs Ekkehard Schiitz, Yuh-Min (Johnson) Andrea President & Chief MD, PHD, FADLM Chiang, PHD James Executive Officer Chief Science Officer Chief Technology Chief Financial Officer Off
Slide 5: Investment Summary
iIMDx Investment Summary (1) See appendix slides 33, 34 and 35 iMDxinc.com Disruptive approach to molecular diagnostic testing: Empower local labs to test in-house with kits, versus sending out to central labs Proven credibility in first strategic market: Kidney transplant®) Go-to-market strategic p
Slide 6: Sending patient samples across the country is a waste of time
j M D ° Insight Molecular Diagnostics Sending patient samples across the country Is a waste of time. iMDxinc.com
Slide 7: Innovative science meets simple business model
Insight Molecular Diagnostics Innovative science meets simple business model
Slide 8: Kitted: Designing a lab test for a box
iIMDx’ Kitted: Designing a lab test for a box
Slide 9: Building a kitted product engine
Building a kitted product engine : Y High Clinical Demand v¥ Strong Reimbursement Vv IP Protected
Slide 10: Full R&D pipeline to fuel decade of growth
IMDx’ Full R&D pipeline to fuel decade of growth GraftAssureGs” GraftAssure Gas Transplant GraftAssurefs DETERMAS DETERMA&" Oncology Onco r iMDxinc.com
Slide 11: Kitted transplant testing is a $2B+ greenfield global opportunity
IMDx° Insight Molecular Diagnostics Kitted transplant testing Is a $2B+ greenfield global opportuni source: 2004 GODT data cuppocts. 128,990 glabal ann) transplants (£10,467 far Key, 10,267 fr heart and 8,236 for lng tameplants}) Hodian graft curva rat of 117 years for Kiney per SRTR, 11.9 yers for
Slide 12: High Clinical Demand
w ™ Dx High Clinical Demand Insight Molecular Diagnostics “High-quality, standardized decentralized dd-cfDNA testing is the essential prerequisite for conducting real-world evidence- generating multicenter studies to establish the appropriate context of use for this promising assay.” — January 2026
Slide 13: Strong Reimbursement
iia: IMDx Strong Reimbursement | | | i U.S. Medicare reimbursement listing of $2,753 per result based uf on MolDx Test Registry pricing for GraftAssureCore — per CPT code 81479 and DEX Z-code Z0507 (https://app.dexzcodes.com) 4 I tii) il iMDxinc.com | l : Mie
Slide 14: IP Protected
IMDx° Insight Molecular Diagnostics 2) United States Patent Schutz et al. (10) Patent No: — US 11,155,872 B2 (45) Date of Patent: Oct. 26, 2021 IP Protected (71) Applicant: CHRONIX BIOMEDICAL CA (US) B) (72) Inventors: Ekkehard Schutz, Gottin Julia Beck Gottingen [03) Asiance: Chrnis Biomed, San Jo5
Slide 15: Customers want a kitted product
; M D ° Insight Molecular Diagnostics Customers want a kitted product Large market opportunity
Slide 16: GraftAssureDx planned for 2026
™ Dx Insight Molecular Diagnostics GraftAssureDx ... planned for 2026 W Transplant Product Design, 2012 CMS — Center for Medicaid Services & Initial Peer-Reviewed Publication, 2013! LDT — Lab Developed Test YA ag i a P RUO — Research Use Only W. Definitive Clinical Publication, 20192 FDA — US Food a
Slide 17: How we win: Deliver what decision makers want
iIMDx’ How we win: Deliver what decision makers want iMDxinc.com Transplant Physicians Y Control v Fast turnaround times Vv Ability to conduct their own research Lab Directors v In-house testing v Simple workflow v Full data access Hospital Administrators v Revenue generation Opportunities v Researc
Slide 18: Transplant hospitals already perform most tests in house
Transplant hospitals already perform most tests in house. Our kits are a natural fit. mmediate Post-Op Intermediate Long-Term Ongoing ABO Blood Typing Therapeutic Drug Monitoring (TDM) Kid-cfDNA (Liquid Biopsy) Metabolic Panel HLA Typing Graft Markers (Kidney) Viral Load PCR DSA Screen PRA / DSA Scr
Slide 19: iMDx + Strategic Partnership
iIMDx' + Strategic Partnership v Bio-Rad (NYSE: BIO) is a top five shareholder and has made three prior equity investments in iMDx Y Our test runs on the Bio-Rad platform Y Coordinated rapid development of test kits ¥ Opportunity for partnership expansion, milestone-based investments iMDxinc.com 19
Slide 20: iMDx + Bio-Rad
iMDx + Bio-Rad ¥ Demonstrating clinical utility of digital PCR ¥ Opening academic hospital core and HLA labs to Bio-Rad platform ¥ 2026: Expect to receive FDA clearance for GraftAssureDx (kidney) for the QX600Dx ¥ Goal (with new capital) of i showcasing the digital PCR advantage in heart transplant
Slide 21: GraftAssure Deployments
GraftAssure Deployments > 22 Sites » 9 Countries » 3 Continents > Institutes planning to publish multiple abstracts in 2026 >» Third party head-to-head data emerging that is favorable to iMDx Many names redacted for competitive sensitivity RUO = Research Use Only Transplant Center Laboratory Custome
Slide 22: On the cusp of FDA submission for GraftAssureDx (kidney)
On the cusp of FDA submission for GraftAssureDx (kidney). Goal of expanding rapidly into heart transplant testing $105 million estimated TAM in the United States $240 million estimated TAM globally v Significance of cfDNA results of heart will increase site adoption ¥ Higher testing frequency per pa
Slide 23: IP attractive to industry partners
iIMDx Insight Molecular Diagnosties IP attractive to industry partners Multiple strategic partnership opportunities IP Category | Products| Product Partner Service Lab Partner GraftAssurees” Bio-Rad signed Q2 Organ Transplant Graft\ssure@3" | 2024, potential for Targeted Q1 2026 expansion GraftAssur
Slide 24: Compelling business model
™ Dx Insight Molecular Diagnostics Compelling business model [aug & High-value creation Empowers doctors to reduce uncertainty to make better decisions to save lives. Enables researchers to measure biomarkers to inspire innovation. High-value capture Intellectual property protects our market positio
Slide 25: A pure play on major industry tailwinds
A pure play on major industry tailwinds Precision Localized Rapid medicine care care Genomics Diagnostics trend Liquid biopsy is less innovation enables toward the patient. invasive. Digital PCR is personalized Decentralized simple, fast, and easy to medicine. healthcare means the use. market trends
Slide 26: Investment Summary Recap
™ Insight Molecular Diagnostics IMDx Investment Summary Recap © Disruptive approach to molecular diagnostic testing Empower local labs with kits Stronger business model Proven, more affordable, faster tests @ Science-driven team, experienced in molecular diagnostics and rapid growth @ Proven credibi
Slide 27: Appendix
‘-MDx’ Insight Molecular Diagnostics Appendix iMDxinc.com
Slide 28: Molecular diagnostics 101
Molecular dia ee Molecular diagnostic testing combines laboratory testing with the precision of molecular biology and has revolutionized the way clinical and public health laboratories investigate the human, viral, and microbial genomes, their genes, and the products they encode. Molecular diagnosti
Slide 29: Transplant testing matters
Insight Molecular Dingnost Transplant testing matters Kidney transplant patients face a 1 ins iMDx’s test finds early chance that their body evidence of organ will reject the donor damage in the blood. kidney. Source on “1 in 5 chance:” Specifically, Antibody-mediated rejection (AMR) is a leading ca
Slide 30: Donor-derived cell-free DNA biomarker
™ Insight Molecular Diagnostics Donor-derived BMWAtraly-ync cell-freeDNA BeScliigiuiic (dd-cfDNA) biomarker Sources: Our timeline slide supports this statement, as well as the fact that MoIDX, a program that identifies and establishes coverage and U.S. government reimbursement for molecular diagnost
Slide 31: New England Journal of Medicine study
™ Insight Molecular Diagnostics New England Journal of Medicine study ¢ Favorable iMDx GraftAssureCore study results published in NEJM, May 30, 2024 ¢ Data show potential to monitor for therapeutic efficacy and recurrence ¢ Potential repeat testing opportunities with claims expansion iMDxinc.com GQ)
Slide 32: Transplant: Leading the science
r ™ Insight Molecular Diagnostics Transplant: Leading the science Our centralized assay, GraftAssureCore, has been THERAPEUTIC DRUG validated in clinical studies with an aggregate of 1,214 “lle patients and 4,917 samples. 226 Liver Recipients PLoS Med (2017), Liver Transpl (2022)?, Transplantation (
Slide 33: Our formula
4 iMDx’ Our formula it Regulated el +Reimbursed | + Clinically Useful | = Rapid Adoption |
Slide 34: iMDx's product appeal
iIMDx" IMDx’s product appeal Transplant v easy to use and centers want v returns a same day answer that is . Y Clinically actionable and a test that is Y cost effective li ‘eCore, formerly known as VitaGraft Kidney LDT, has clinical claim. iMDx jing regulatot AND a authorization for kitted products
Slide 35: iMDx Compelling Patent Portfolio
IMDx Compelling Patent Portfolio TEST STATUS | PATENTNUMBER | _ ISSUED DATE PATENT EXPIRATION DetermaCNI*|Prostate Cancer Associated Circulating Nucleic Acid Biomarkers United States of America| Issued 10214775 Feb 26,2019 —_|Dec 7, 2032+ 687 days PTA DetermaCNI |Breast Cancer Associated Circulating
Slide 36: TM X ta it | , i} ' il II
TM X ta it | , i} ' il II Insight Molecular Diagnostics
Insight Molecular Diagnostics — Investor Presentation (February 2026) on 6ix